中文

共同药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.16B+16.3%
Gross profit¥0.04B
Operating income¥-0.00B
Net income¥0.00B
Gross margin22.8%Net margin 0.7%
Revenue Q/Q+7.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.12B77.2%
R&D¥0.01B7.6%
SG&A¥0.01B7.4%
Tax & other¥-0.00B-1.5%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

晓鸣股份格林精密恒帅股份华绿生物博亚精工万辰集团立高食品商络电子达瑞电子深圳瑞捷东箭科技华利集团

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies